GlassScriptPhysician profile
Kerry Harris
NPI 1164738399
$3,116.14
in general payments reported to CMS, 2019-2025
13 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $233 · 2022: $85.41 · 2023: $441 · 2024: $1,170 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.65 |
| Education | $186.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $873.23 | 2023-2025 | |
| Janssen Biotech, INC. | $665.34 | 2023-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.89 | 2021-2024 | Xifaxan |
| Pfizer INC. | $279.22 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $235.59 | 2021-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $228.22 | 2024 | Voquezna |
| Ardelyx, INC. | $163.21 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $140.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $41.53 | 2023 | Talicia |
| Nestle Healthcare Nutrition INC. | $32.22 | 2023 | |
| Gilead Sciences, INC. | $23.50 | 2025 | |
| Celltrion USA INC. | $19.94 | 2025 | Vegzelma |
| Novo Nordisk INC | $15.74 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.